Snakebite care in dogs sharpens around antivenom and triage

Snakebite care in dogs is evolving, but not in a way that displaces the basics. Across recent veterinary literature, the clearest message is that antivenom plus aggressive supportive care still anchors treatment, while newer adjunctive options, including varespladib, hemoperfusion, and plasma exchange, remain investigational or early-stage. A 2026 review in Frontiers in Veterinary Science framed these therapies as promising, but concluded that antivenom administration and supportive care are still the mainstays of care. (frontiersin.org)

That matters because snake envenomation remains a time-sensitive emergency with highly variable presentations depending on the snake, venom type, bite location, venom dose, and patient factors. The literature reviewed by Frontiers and other veterinary references describes a field still working around uneven evidence, regional antivenom availability, cost constraints, and differences between species and venom syndromes. Merck’s veterinary guidance continues to recommend rapid examination, close monitoring, IV crystalloid support for hypotension, pain control, and serial assessment of swelling and coagulopathy in crotalid cases. (frontiersin.org)

The newer wrinkle is interest in therapies that may blunt venom effects beyond conventional antivenom. The Frontiers review highlighted varespladib, a phospholipase A2 inhibitor, as one of the most discussed candidates, and also pointed to carbon monoxide-releasing molecules, hemoperfusion, and total plasma exchange as areas of active investigation. Still, the same review was careful about the limits: much of this work is preclinical, translational, or based on early clinical experience, and significant barriers remain around timing, cost, and proving benefit in naturally envenomated veterinary patients. (frontiersin.org)

For therapies already in use, the evidence continues to support antivenom when clinically indicated. In a prospective multicenter observational study published in Journal of Veterinary Emergency and Critical Care, 82 client-owned dogs with progressive viper envenomation were treated with equine-derived polyvalent F(ab')2 antivenom. Most dogs showed improved snakebite severity scores at 4 hours and 8 hours after treatment, and five dogs died. Antivenom-related acute or intermediate reactions occurred in 12 dogs, or 14.6%, underscoring both the value of treatment and the need for close monitoring during administration. (pubmed.ncbi.nlm.nih.gov)

At the same time, some long-standing questions in snakebite care are being revisited. Merck notes that commonly attempted first-aid steps, including ice, incision and suction, tourniquets, electric shock, hot packs, and waiting for symptoms to worsen, are ineffective or potentially harmful. It also says the incidence of wound infection after snakebite is low, and many veterinarians reserve antimicrobials for cases with notable tissue necrosis. That aligns with a veterinary evidence review indexed in PubMed, which found routine antimicrobial use after snakebite isn’t supported by the available evidence, although stronger studies are still needed. (merckvetmanual.com)

Why it matters: For veterinary teams, this is less a story about a breakthrough than about clinical refinement. The emerging literature supports faster, more disciplined decision-making around triage, antivenom selection, coagulation monitoring, analgesia, and case-by-case use of adjunctive therapies. It also highlights a practical reality many clinicians already know: outcomes can depend not just on biology, but on whether a hospital has antivenom on hand, whether a pet parent can absorb the cost of multiple vials and hospitalization, and whether the team can monitor for complications such as shock, coagulopathy, tissue injury, or hypersensitivity reactions. (merckvetmanual.com)

There’s also a growing sense that veterinary medicine needs more species-specific evidence rather than borrowed assumptions from human toxicology. The Frontiers authors described a relative paucity of comparative literature and argued that better understanding of mechanisms, treatment response, and novel therapies is needed to move the field forward. Inference: that likely means future progress will come less from dramatic one-off interventions and more from multicenter veterinary studies that clarify which dogs benefit most, how to dose and time antivenom more consistently, and whether adjuncts like varespladib can improve outcomes when added to standard care. (frontiersin.org)

What to watch: The next phase will likely center on veterinary-specific data for adjunctive therapies, more standardized treatment pathways, and continued debate over how to balance early antivenom use, adverse-reaction risk, availability, and cost in real-world emergency practice. (frontiersin.org)